HOTTIP recruits EZH2 to participate in drug resistance, suggesting that Tazemetostat could be used as an adjuvant in CML patients with high HOTTIP expression. The gene discussed is EZH2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.